TheStreet downgraded shares of Misonix (NASDAQ:MSON) from a c- rating to a d rating in a research note released on Thursday morning, TheStreetRatingsTable reports.

Separately, BTIG Research initiated coverage on Misonix in a report on Wednesday, June 12th. They issued a buy rating and a $29.00 price target on the stock. Four investment analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and a consensus price target of $27.00.

Shares of NASDAQ:MSON opened at $25.34 on Thursday. Misonix has a 12-month low of $12.20 and a 12-month high of $26.41.

Misonix (NASDAQ:MSON) last announced its quarterly earnings results on Wednesday, May 8th. The medical equipment provider reported ($0.17) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.01. Misonix had a negative return on equity of 29.13% and a negative net margin of 18.10%. The business had revenue of $9.56 million for the quarter.

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in Misonix by 15.7% in the 3rd quarter. Vanguard Group Inc. now owns 213,040 shares of the medical equipment provider’s stock valued at $3,941,000 after purchasing an additional 28,889 shares during the period. Acadian Asset Management LLC grew its position in Misonix by 15.7% in the 4th quarter. Acadian Asset Management LLC now owns 9,504 shares of the medical equipment provider’s stock valued at $153,000 after purchasing an additional 1,292 shares during the period. Geode Capital Management LLC grew its position in Misonix by 5.3% in the 4th quarter. Geode Capital Management LLC now owns 35,095 shares of the medical equipment provider’s stock valued at $561,000 after purchasing an additional 1,775 shares during the period. Tibra Equities Europe Ltd acquired a new stake in Misonix in the 1st quarter valued at $327,000. Finally, Rathbone Brothers plc grew its position in Misonix by 6.2% in the 1st quarter. Rathbone Brothers plc now owns 15,500 shares of the medical equipment provider’s stock valued at $298,000 after purchasing an additional 900 shares during the period. Hedge funds and other institutional investors own 21.17% of the company’s stock.

About Misonix

Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.

Read More: Relative Strength Index

Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.